A Big Ten Cancer Research Consortium study, led by investigators at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, could help determine whether an investigational combination of chemotherapy drugs might lead to improved overall responses in patients with metastatic or advanced unresectable gastric/GE junction cancer.

The goal of the single-arm, phase II study, known as BTCRC-GI15-015, is to estimate the overall objective response rate in subjects receiving the combination of FOLFOX and nab-paclitaxel (FOLFOX-A).

Al B. Benson III, MD, is sponsor-investigator of the study; Mary F. Mulcahy, MD, and Sheetal M. Kircher, MD, also of Northwestern, are co-investigators.

The Big Ten Cancer Research Consortium will host meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups during ASCO 2018.

The following meetings will be at the Holiday Inn Chicago Mart Plaza River North, 350 West Mart Center Drive, Chicago, Ill. See map. All times are CT. Refreshments will be served.  For more information, contact Abigail Proctor at [email protected] , or call 317-634-5842, ext. 43.

6:00-6:30 pm: Big Ten CRC Foundation
6:30-7:30 pm: Cancer Center Directors
7:30-9:00 pm: Steering Committee

7:00-8:00 pm: Thoracic CTWG
8:30-9:30 pm: Gastrointestinal CTWG

7:00-8:00 pm: Genitourinary CTWG
8:30-9:30 pm: Head and Neck CTWG

Visit the Big Ten CRC  at booth #25099 in the exhibit hall, in McCormick Place South, Hall A.

An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002

Sponsor-investigator:

Bert O'Neil, MD, Indiana University

William J. Gradishar, MD, the Betsy Bramsen professor of breast oncology & professor of medicine in the Division of Hematology and Oncology and director of the clinical network of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, has been appointed chief of the Division of Hematology and Oncology at the Feinberg School of Medicine, effective April 1, 2018. An internationally recognized expert on breast cancer management and a member of the Big Ten CRC's Breast Clinical Trial Working Group, Dr. Gradishar's clinical and research efforts are focused on the development of novel therapies.

Richard and Susan Rogel are on a mission to boost innovative cancer research and develop the next generation of cancer pioneers -- and they are committing $150 million to the University of Michigan Comprehensive Cancer Center to realize that vision. The University of Michigan Regents recently approved a new name for the cancer center, in honor of the Rogels.